Pfizer Reaffirms FY23 Guidance Provided In October Of Revenues Of $58B-$61B And Adjusted EPS Of $1.45-$1.65

Pfizer Reaffirms FY23 Guidance Provided In October Of Revenues Of $58B-$61B (Consensus Of $59.82B) And Adjusted EPS Of $1.45-$1.65 (Consensus Of $1.59)